Article info
PDFEditors’ commentary
Highlights from this issue
- Correspondence to Dr Geraint N Fuller, Gloucester Royal Hospital, Gloucester GL1 3NN, UK; geraint.fuller{at}glos.nhs.uk
Citation
Highlights from this issue
Publication history
- Accepted April 19, 2017
- First published May 26, 2017.
Online issue publication
July 05, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Other content recommended for you
- Guanidinoacetate methyltransferase (GAMT) deficiency: a rare but treatable epilepsy
- P19 Clinical pearl: pharmaceutical management of siblings with guanidinoacetate methyltransferase (gamt) deficiency
- Phenotype and genotype in 101 males with X-linked creatine transporter deficiency
- GP223 Creatine deficiency disorders the all-ireland experience
- 4CPS-188 Galenic preparations and rare diseases: guanidinoacetate methyltransferase deficiency: experience in a local hospital
- POE05 A low creatinine in developmental delay, epilepsy and movement disorders—does it matter?
- PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease
- Neurodegenerative disorders and metabolic disease
- Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide
- Contemporary management of low-grade glioma: a paradigm shift in neuro-oncology